The overall approach for the therapeutic analysis of the IGF-I and BTP-2 therapies for LPS-induced ALI was to focus on three essential biologic processes of inflammation and repair—namely, (1) increased production of the proinflammatory cytokines, (2) impaired vascular function, and (3) improved repair (or less injury). This evidence concerns the gene IGF1 and acute respiratory distress syndrome.